ATE287402T1 - Nanomolare, non-peptidische inhibitoren von cathepsin d - Google Patents
Nanomolare, non-peptidische inhibitoren von cathepsin dInfo
- Publication number
- ATE287402T1 ATE287402T1 AT98904934T AT98904934T ATE287402T1 AT E287402 T1 ATE287402 T1 AT E287402T1 AT 98904934 T AT98904934 T AT 98904934T AT 98904934 T AT98904934 T AT 98904934T AT E287402 T1 ATE287402 T1 AT E287402T1
- Authority
- AT
- Austria
- Prior art keywords
- cathepsin
- nanomolar
- peptidic inhibitors
- peptidic
- inhibitors
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/44—Iso-indoles; Hydrogenated iso-indoles
- C07D209/48—Iso-indoles; Hydrogenated iso-indoles with oxygen atoms in positions 1 and 3, e.g. phthalimide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
- A61K31/36—Compounds containing methylenedioxyphenyl groups, e.g. sesamin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/4035—Isoindoles, e.g. phthalimide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/423—Oxazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
- C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
- C07D263/58—Benzoxazoles; Hydrogenated benzoxazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
- C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
- C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
- C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
- C07D317/50—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to atoms of the carbocyclic ring
- C07D317/58—Radicals substituted by nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
- C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
- C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
- C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
- C07D317/50—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to atoms of the carbocyclic ring
- C07D317/60—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
- C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
- C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
- C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
- C07D317/62—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to atoms of the carbocyclic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US3690397P | 1997-02-04 | 1997-02-04 | |
PCT/US1998/002199 WO1998033795A1 (en) | 1997-02-04 | 1998-02-03 | Nanomolar, non-peptide inhibitors of cathepsin d |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE287402T1 true ATE287402T1 (de) | 2005-02-15 |
Family
ID=21891303
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT98904934T ATE287402T1 (de) | 1997-02-04 | 1998-02-03 | Nanomolare, non-peptidische inhibitoren von cathepsin d |
Country Status (8)
Country | Link |
---|---|
US (1) | US6150416A (de) |
EP (1) | EP0958293B1 (de) |
JP (1) | JP2001510474A (de) |
AT (1) | ATE287402T1 (de) |
AU (1) | AU749281B2 (de) |
CA (1) | CA2280096A1 (de) |
DE (1) | DE69828682T2 (de) |
WO (1) | WO1998033795A1 (de) |
Families Citing this family (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7119105B2 (en) | 1997-02-04 | 2006-10-10 | The Regents Of The University Of California | Methods for treating neurodegenerative disorders using aspartyl protease inhibitors |
US6542858B1 (en) | 1998-09-14 | 2003-04-01 | Lion Bioscience Ag | Pharmacokinetic-based drug design tool and method |
EP1178800A4 (de) * | 1999-03-24 | 2002-07-31 | Univ California | Verfahren zur Behandlung von Neurodegenerativen Störungen unter Verwendung der Inhibitoren von Aspartyl-Protease |
WO2001050124A1 (en) * | 2000-01-03 | 2001-07-12 | The Trustees Of Princeton University | High efficiency mapping of molecular variations to functional properties |
US7034182B2 (en) * | 2000-06-30 | 2006-04-25 | Elan Pharmaceuticals, Inc. | Compounds to treat Alzheimer's disease |
US6846813B2 (en) * | 2000-06-30 | 2005-01-25 | Pharmacia & Upjohn Company | Compounds to treat alzheimer's disease |
EP1586556A3 (de) * | 2000-06-30 | 2005-12-21 | Elan Pharmaceuticals, Inc. | Verbindungen zur Behandlung der Alzheimerischen Krankheit |
PE20020276A1 (es) * | 2000-06-30 | 2002-04-06 | Elan Pharm Inc | COMPUESTOS DE AMINA SUSTITUIDA COMO INHIBIDORES DE ß-SECRETASA PARA EL TRATAMIENTO DE ALZHEIMER |
EP1666452A2 (de) | 2000-06-30 | 2006-06-07 | Elan Pharmaceuticals, Inc. | Verbindungen zur Behandlung der Alzheimerischen Krankheit |
US20030211487A1 (en) * | 2001-01-03 | 2003-11-13 | Herschel Rabitz | High efficiency mapping of molecular variations to functional properties |
AR035960A1 (es) * | 2001-04-23 | 2004-07-28 | Elan Pharm Inc | Epoxidos sustituidos y procesos para prepararlos |
AU2002314914A1 (en) * | 2001-06-01 | 2002-12-16 | Elan Pharmaceuticals, Inc. | Hydroxy alkyl amine derivatives as beta-secretase inhibitors and their use for the treatment of alzheimer's disease and similar diseases |
CA2462851A1 (en) | 2001-10-04 | 2003-04-10 | Elan Pharmaceuticals, Inc. | Hydroxypropylamines |
TW200304808A (en) * | 2001-11-08 | 2003-10-16 | Elan Pharm Inc | N,N'-substituted-1,3-diamino-2-hydroxypropane derivatives |
MXPA04004772A (es) | 2001-11-19 | 2005-06-06 | Elan Pharm Inc | Piperidinas y piperazinas 3,4-disustituidas, 3,5-disustituidas y 3,4,5-sustituidas. |
WO2004058686A1 (en) | 2002-04-30 | 2004-07-15 | Elan Pharmaceuticals, Inc. | Hydroxypropyl amides for the treatment of alzheimer’s disease |
WO2004000838A1 (en) * | 2002-06-24 | 2003-12-31 | Axys Pharmaceuticals, Inc. | Peptidic compounds as cysteine protease inhibitors |
AP2005003247A0 (en) * | 2002-09-10 | 2005-03-31 | Pharmacia & Upjohn Co Llc | Acetyl 2-hydroxy-1,3 diaminoalkanes. |
UY27967A1 (es) * | 2002-09-10 | 2004-05-31 | Pfizer | Acetil 2-hindroxi-1,3-diaminoalcanos |
GB0228410D0 (en) * | 2002-12-05 | 2003-01-08 | Glaxo Group Ltd | Novel Compounds |
GB0309221D0 (en) * | 2003-04-23 | 2003-06-04 | Glaxo Group Ltd | Novel compounds |
US7408008B2 (en) | 2003-12-09 | 2008-08-05 | Janssen Pharmaceutica, N.V. | Method of producing highly functionalized 1,3-diamino-propan-2-ols from solid support |
GB0328900D0 (en) * | 2003-12-12 | 2004-01-14 | Glaxo Group Ltd | Novel compounds |
WO2006102760A1 (en) * | 2005-04-01 | 2006-10-05 | Methylgene Inc. | Inhibitors of histone deacetylase |
ES2649964T3 (es) | 2011-02-08 | 2018-01-16 | Merck Patent Gmbh | Derivados de aminoestatina para el tratamiento de la artrosis |
ES2673873T3 (es) | 2012-07-24 | 2018-06-26 | Merck Patent Gmbh | Derivados de hidroxiestatina para el tratamiento de la artrosis |
WO2014084430A1 (ko) * | 2012-11-30 | 2014-06-05 | 경상대학교 산학협력단 | 병용 항암요법 |
JP6321685B2 (ja) | 2013-02-25 | 2018-05-09 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングMerck Patent Gesellschaft mit beschraenkter Haftung | 2−アミノ−3,4−ジヒドロ−キナゾリン誘導体、およびそのカテプシンd阻害剤としての使用 |
EP3030250B1 (de) | 2013-08-06 | 2019-08-28 | Merck Patent GmbH | Intraartikuläre applikation von pepstatin bei arthrose |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4604402A (en) * | 1984-03-30 | 1986-08-05 | E. R. Squibb & Sons, Inc. | Hydroxy substituted ureido amino and imino acids |
DK0558657T3 (da) * | 1990-11-19 | 1997-07-07 | Monsanto Co | Retrovirale proteaseinhibitorer |
-
1998
- 1998-02-03 WO PCT/US1998/002199 patent/WO1998033795A1/en active IP Right Grant
- 1998-02-03 EP EP98904934A patent/EP0958293B1/de not_active Expired - Lifetime
- 1998-02-03 AU AU62686/98A patent/AU749281B2/en not_active Ceased
- 1998-02-03 DE DE69828682T patent/DE69828682T2/de not_active Expired - Lifetime
- 1998-02-03 US US09/018,226 patent/US6150416A/en not_active Expired - Lifetime
- 1998-02-03 JP JP53323698A patent/JP2001510474A/ja not_active Ceased
- 1998-02-03 CA CA002280096A patent/CA2280096A1/en not_active Abandoned
- 1998-02-03 AT AT98904934T patent/ATE287402T1/de not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
DE69828682T2 (de) | 2006-04-06 |
CA2280096A1 (en) | 1998-08-06 |
DE69828682D1 (de) | 2005-02-24 |
EP0958293A1 (de) | 1999-11-24 |
US6150416A (en) | 2000-11-21 |
AU749281B2 (en) | 2002-06-20 |
JP2001510474A (ja) | 2001-07-31 |
EP0958293B1 (de) | 2005-01-19 |
AU6268698A (en) | 1998-08-25 |
WO1998033795A1 (en) | 1998-08-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE287402T1 (de) | Nanomolare, non-peptidische inhibitoren von cathepsin d | |
ATE209191T1 (de) | Parazinon thrombin inhibitoren | |
ID18142A (id) | Inhibitor metaloprotease 1,4-heterosiklik | |
ID18141A (id) | Inhibitor metaloprotease 1,3-diheterosiklik | |
ATE328874T1 (de) | Substituieten triazoldiamin derivaten und ihre verwendung als kinase inhibitoren | |
ID18416A (id) | Inhibitor metaloprotease diheterosiklik | |
DE69716916D1 (de) | Kondensierte heterozyklische verbindungen als protein kinase inhibitoren | |
ATE236165T1 (de) | Substituierte stickstoff enthaltende heterocyclen als p38 protein kinase inhibitoren | |
ATE214693T1 (de) | Aminoguanidine und alkoxyguanidine als protease- hemmer | |
NO990856D0 (no) | Spirosykliske metallprotease-inhibitorer | |
DK0956294T3 (da) | Thrombininhibitorer | |
ATE366110T1 (de) | Verwendung von inhibitoren des renin-angiotensin systems | |
ATE332919T1 (de) | Inhibitoren von phosphoserin- und phosphothreoninspezifischen isomerasen | |
ID16104A (id) | Inhibitor-inhibitor serin protease. | |
ATE264328T1 (de) | Substituierte 3-cyano-(1.7), (1.5) und (1.8)naphthyridininhibitoren von tyrosin kinasen | |
ATE211719T1 (de) | Korrosionsinhibitoren enthaltender injektionszement | |
NO20033921L (no) | Inhibitor av monoaminopptak | |
DE69731664D1 (de) | Thrombininhibitoren | |
BR0110205A (pt) | Inibidores de peptìdeo deformilase | |
DE69916150T2 (de) | Erfassung von Fälschungen | |
DE59910945D1 (de) | Hemmung von alopezie | |
ATE433953T1 (de) | Peptiddeformylaseinhibitoren | |
FI961299A0 (fi) | Cysteinproteinasinhibitorernas genteknologiska anvaendning foer foerhindrandet av vaevnadsdegeneration | |
HUP9802616A2 (hu) | DUEIMVIO fajtanevű, teltvirágú sötétrózsaszínű muskátli (Pelargonium Zonale Hybridae) |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |